Generierung eines Nierenzellkarzinommodells: Ein Protokoll zur Entwicklung eines orthotopen RCC-Mausmodells durch intrarenale Implantation von Krebszellen

Executive Industry Relevance

Orthotopic renal cell carcinoma models enable physiologically relevant tumor growth and metastasis, providing a predictive platform for preclinical therapy evaluation. This approach supports target validation and mechanistic de-risking by recapitulating human disease biology in vivo. The model enhances confidence in lead identification and portfolio triage for RCC-directed therapeutics.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of therapeutic hypotheses in a disease-relevant microenvironment.
• Operational Value: Supports functional target validation through observable primary tumor formation and metastatic spread.
• Strategic Value: Improves predictive confidence for target prioritization and pathway modulation studies.

Screening & Assay Development

• Scientific Value: Generates quantifiable tumor growth and metastasis readouts for compound screening.
• Operational Value: Delivers reproducible orthotopic engraftment enabling standardized assay conditions.
• Strategic Value: Facilitates dose-response and efficacy profiling in a clinically predictive model.

Translational & Preclinical Research

• Scientific Value: Models metastatic progression to lung, mirroring human RCC dissemination patterns.
• Operational Value: Allows longitudinal monitoring of tumor burden and treatment response over time.
• Strategic Value: Informs risk-adjusted advancement decisions by capturing both primary and secondary tumor dynamics.

Pipeline & Workflow Integration

The orthotopic RCC model integrates into the discovery continuum from target validation through lead optimization to preclinical efficacy testing, enabling seamless transition across stages.

• Discovery Biology: Supports hypothesis testing of tumor initiation, growth, and metastatic potential in vivo.
• Screening: Provides assay-ready tumors with measurable endpoints for therapeutic intervention studies.
• Analytics: Yields quantitative bioluminescent or volumetric tumor measurements enabling comparative condition analysis.
• Translational Research: Connects early mechanistic findings to preclinical validation through clinically relevant metastasis.
• Enterprise Reuse: Establishes a reusable platform for evaluating multiple RCC therapeutics across projects.

Operational & Enterprise Impact

• Scientific Value: Reduces mechanistic ambiguity by modeling tumor-stroma interactions in the renal microenvironment.
• Operational Value: Ensures reproducibility through standardized surgical implantation and cell preparation protocols.
• Strategic Value: Enhances go/no-go decision-making by predicting clinical translatability of RCC candidates.
• Portfolio Impact: Enables risk-based resource allocation by distinguishing compounds with true anti-metastatic activity.

Implementation Considerations

• Requires expertise in murine surgical techniques and anesthesia management.
• Dependent on sterile instrumentation, tissue adhesives, and cell preparation biosafety practices.
• Necessitates cross-team standardization between oncology, pharmacology, and surgical teams.
• Involves adaptation considerations for different RCC cell lines and genetic backgrounds.
• Limited by the need for immunocompromised hosts, which restricts immune-oncology applicability.

Biopharma FAQs